Since its launch in 2002, the Global Fund has approved funding support for 150 countries. These have included the poorest countries in the world, including Liberia, the Democratic Republic of Congo and Burundi, but also upper middle-income countries, such as Argentina, Brazil, and China.

Breakdown of funding by disease type: Of the US$22.9 billion that the Global Fund has approved to date, 53% was allocated to HIV/AIDS, while 28% was allocated to malaria and 17% to TB (see Approved funding by disease).

Data source: Global Fund grant portfolio, as of January 17, 2012

Breakdown of funding by region: More than half of all approved funding (55.2%) is allocated to the three Sub-Saharan African sub-regions—East Africa, West and Central Africa, and Southern Africa (see Approved funding by region). A Global Fund analysis found that the share of approved funding in each region is broadly in line with that region’s share of the global burden of HIV, TB, and malaria (see the Global Fund 2010 report Innovation and Impact, figure 2.23).

Data source: Global Fund grant portfolio, as of January 17, 2012

Breakdown of funding by country income group: About 46% of Global Fund financing goes to low-income countries, and about 34% to lower middle-income countries. Upper middle-income countries account for 17% of funding. The remaining 3% go to multi country proposals, high-income countries and to countries not classified according to income level.

Breakdown of funding by top recipient countries: About 37% of all approved funds (US$8.5 billion out of US$22.9 billion) are channeled to 10 out of the 150 countries and multi-country proposals that have received Global Fund support as of December 2011 (see Top 10 recipients). The same ten countries also account for 38% of the Global Fund’s total lifetime budget (US$13.0 billion out of US$34.2 billion).

Data source: Global Fund grant portfolio, as of January 17, 2012

Further information on the breakdown of funding—by Round, type of Principal Recipient, and service delivery area (e.g., TB prevention versus treatment)—can be found here.

Detailed information on the Global Fund’s financing portfolio can be found here and here.

The Affordable Medicines Facility-malaria (AMFm)

The AMFm, an innovative financing mechanism aimed at expanding access to artemisin-based combination therapies (ACT) for malaria treatment, is hosted and managed by the Global Fund as a separate business line.

The mechanism, which is currently being piloted in eight countries, involves a donor subsidy to lower the cost of ACTs purchased by eligible first-line buyers. If the subsidy then gets passed on in turn along the supply chain to consumers, this should lead to reduced consumer prices for ACTs, which should increase ACT usage rates. The results of an independent evaluation of the pilot will become available in 2012.

Read more about the AMFm.